click enter text
upgrad outperform
upgrad outperform cro stock perform
weak thu far see driven combin mix
result anxieti biotech fund posit believ
overdon take opportun upgrad
outperform peer perform high-level see estim
achiev valuat less potenti barrier out-performance
think prah multipl could re-rat book growth improv
outperform clearli tough year compani
driven combin revenu guide-down w/ result flattish gross
book moder net book-to-bil ratio compani see
issu larg exogen above-averag turnov upon vest pre-ipo
option slower ramp-up new prefer provid relationship slower
book prah largest custom takeda integr shire
acquisit ceo colin shannon say compani turn new
busi didnt feel properli staf handl rather potenti
jeopard long-term relationship prah new hire
run mani non-compet longer issu
addit shire expect move onto takeda oper platform
greenfield opportun expect would
least help off-set synergi gener legaci takeda side
busi final see reason path sequenti improv
net book-to-bil import driver sentiment acknowledg
visibl remain low see risk/reward skew posit valuat
would approach synh-level gener materi downsid
outperform set new high follow compani
impress june investor day under-perform xlv
 solid moment book view
primari driver consensu est close align
manag expect toward lower end medium-
term ebitda growth y/i vs see smaller
risk neg estim revis follow result guidanc
target price year-end target price increas
upsid previous assum trade pariti w/
 vs discount previous target price remain
upsid assum trade premium vs
premium previous stabl target price driven higher
market multipl addit detail sensit avail note
report limit sole use client wolf research pleas refer disclosur section locat end
report analyst certif import disclosur disclosur
page
upgrad outperform
cro stock perform weak thu far see driven combin mix
result anxieti biotech fund posit take opportun upgrad
outperform peer perform high-level see estim achiev valuat less
potenti barrier out-performance think prah multipl could re-rat book growth
improv could start earli
exhibit ytd price perform vs xlv
compani data factset wolf research llc
exhibit ytd price perform vs xlv
compani data factset wolf research llc
page
rel rel rel rel xlv
note total return reflect annual dividend yield compar year-end price target
compani data factset wolf research llc
outperform peer perform
clearli tough year compani driven combin revenu guide-down w/ result
flattish gross net book moder net book-to-bil ratio
exhibit net new busi award
exhibit net book-to-bil basi
compani data factset wolf research llc
compani data factset wolf research llc
page
compani see issu larg exogen above-averag turnov upon vest pre-ipo option slower
ramp-up new prefer provid relationship slower book prah largest custom takeda
integr shire acquisit
prah new hire run mani non-compet longer issu
addit shire expect move onto takeda oper platform greenfield opportun
expect would least help off-set synergi gener legaci takeda side
final see reason path sequenti improv net book-to-bil import driver
acknowledg visibl remain low see risk/reward skew posit valuat would approach
synh-level gener materi downsid
past year averag q/q growth gross new busi award
show estim gross new busi award across rang q/q assumpt assum cancel
toward higher-end prah recent experi
revenu estim align prah impli guidanc scenario flat q/q gross new
busi award scenario would result sequenti lower net book-to-bil ratio growth gross new
busi award would produc net book-to-bil revers recent loss momentum also
import driver sentiment stock
compani data factset wolf research llc
page
commentgross new busi chang chang chang q/q growth past year toward higher-end recent experiencenet new busi win less cancel chang chang chang servic revenu less assum small spread vs servic estim align full-year guidanc vs assumpt littl differ vs revenuenet book new award divid
note includ cro averag due signific company-specif valuat swing
compani data factset wolf research llc
note includ cro averag due signific company-specif valuat swing
compani data factset wolf research llc
page
year-end target price upsid repres ebit estim
target ev/ebit multipl target ev/ebit multipl repres pariti
ev/ebit multipl slightli averag in-lin averag
previous assum discount multipl time think could upsid
target price equival ep multipl
compani data factset wolf research llc
page
exhibit summari estim chang comparison consensu estim
exhibit ep bridg
note calcul base ebit margin exampl show posit contribut mean revenu grow quickli
compani data factset wolf research llc
exhibit ep bridg
note calcul base ebit margin exampl show posit contribut mean revenu grow quickli
compani data factset wolf research llc
page
compani data factset wolf research llc
page
outperform peer perform
set new high follow compani impress june investor day under-perform
 xlv solid moment book view primari
beyond improv rel valuat also see increas estim achiev look
consensu estim close align manag expect toward
lower end medium-term ebitda growth y/i vs see smaller risk
neg estim revis follow result guidanc
result expect total compani revenu grow next three year
period contribut overal growth basi point provid
precis guidanc know bare start exercis provid
precis guidanc year tradit custom begin year
anticip top-lin growth project period lower end rang
initi three-year period ramp higher end rang end
time-frame noth els know continu invest innov annual wage
inflat deploy saa solut sell tuck-in technolog acquisit
come usual zero profit loss combin would repres signific headwind
also know much like revenu growth also like margin expans therefor
launch oper excel program final stage detail confer
rest week leadership team final program target addit
million run rate cost save exit precis set action includ entir
organ progress cost save cours linear expect save
ramp approach third year anticip forecast save off-set
headwind talk consequ contribut continu margin expans
page
revenu growth guidanc segment
exhibit comparison medium-term guidanc issu novemb june
iqvia wolf research
origin deal ims/quintil synergi realiz introduc new cost cut program
help off-set continu invest busi wage pressur oce up-front cost low/no margin technolog deal
benefit ramp fairli meaning contribut compani expect ebitda growth acceler
period
exhibit new cut program introduc june investor day
page
note includ cro averag due signific company-specif valuat swing
compani data factset wolf research llc
note includ cro averag due signific company-specif valuat swing
compani data factset wolf research llc
page
year-end target price remain upsid repres ebit estim
target ev/ebit multipl target ev/ebit multipl premium ev/ebit
multipl averag see warrant iqv acceler growth profil
premium assum previous stabl target price driven higher market multipl
equival ep multipl
given signific earn contribut growth profil iqv technolog analyt solut segment
acknowledg potenti sum-of-the-part valuat dont assum
compani data factset wolf research llc
page
exhibit summari estim chang comparison consensu estim
compani data factset wolf research llc
exhibit ep bridg
note calcul base ebit margin exampl show posit contribut mean revenu grow quickli
compani data factset wolf research llc
exhibit ep bridg
note calcul base ebit margin exampl show posit contribut mean revenu grow quickli
compani data factset wolf research llc
page
compani data factset wolf research llc
page
note light blue dark blue shown metric avail
compani data factset wolf research llc
compani data factset wolf research llc
page
cro valuat rel healthcar subsector
exhibit ntm cro price-to-earnings valuat vs healthcar subsector
compani data factset wolf research llc
exhibit ntm cro ev ebit valuat vs healthcar subsector
compani data factset wolf research llc
exhibit ntm cro ev ebitda valuat vs healthcar subsector
compani data factset wolf research llc
page
recent cro commentari biotech fund potenti polit disrupt
morn pleas overal third quarter result highlight high single-digit
organ revenu growth consist long-term target oper margin expans repres
posit step toward achiev target
market demand lead early-stag portfolio remain strong throughout year biotech
fund level number molecul approv fda may end year slightli peak level
industri fundament scientif innov remain robust ever seen outsourc key
client success promis anoth solid year biopharmaceut industri client
discov solut previous unmet medic need use new technolog like cell gene therapi
immunotherapi reli like charl river support research program indic
relationship client spend level affect geopolit rhetor
involv trade war drug price firmli believ client continu partner
charl river order bring new drug market faster effici patient need
earlier prepar comment think guy mention demand environ pretti robust
present howev guess thu far also see kind biotech fund start
cool year-over-year basi still pretti solid dollar basi guy kind start
hear commentari client around kind earli cautionari commentari
ye fund strong long think peopl watch close
indic slowdown answer question time -- keep ask
least year see go slow go
busi fair question realiti fund level still quit substanti reckon
year cash bank capit market plu lot money come directli
pharma would say increasingli money come directli pharma vc fund quit plenti
lot biotech compani bought far year pharma larger biotech
compani hear noth client biotech client base increas dramat
extent constant increas new modal requir outsourc
would hear probabl anyon servic broad gaug mani
client concern hesit term avail fund would begin see mayb
multipl geographi certainli across multipl client mean watch
page
well someth pretti diabol dramat happen caus sort pullback
given strength scienc day
confer
okay great take step back look fundament across relev market
guess give us updat underli demand trend across biopharma custom well
provid us updat biotech fund environ -- would consid healthi
pace saw seem like absolut level seem rel strong speak
overal health biotechnolog
birgit girshick charl river laboratori inc evp discoveri safeti assess
biolog test solut avian vaccin servic
sure happi biotech primari growth driver littl year year
ago went primarili see growth pharma biotech realli busi
fund strong said line actual one best year last year
see particular -base ventur capit compani strong fund also see
fund improv europ see client perspect see
fund biotech client larg pharma see obvious acquisit
bunch year think far also ipo ventur capit
pharma compani either work biotech compani ventur arm in-licens
program biotech compani
also see collabor pharma biotech work biotech
compani risk-shar deal mileston
look pharma client demand curv pharma custom -- servic
see growth busi pharma well except research model
servic busi seen declin larg pharma year come fewer
research program pharma reduc pipelin certainli acquisit
pharma done becom smaller base off-set pharma client china
work research model china china-bas product chines pharma
overal quit happi demand biotech well pharma spent lot time
last year realli prepar prepar portfolio chang market biotech
smaller compani acquisit specif done gain access biotech client
portfolio recent acquisit realli help us drive demand curv servic
client segment biotech specif
page
okay great mayb steve follow-up one earlier question broader dynam
market specif heard feedback custom discuss around
dc issu around drug price control et cetera certainli uncertainti look back
nois around elect caus peopl paus curiou custom
bring hear market peopl say hey drug
price control come sort rethink busi curiou thought
ye sandi get much feedback custom honest say
wish thing effici cost effect certainli case realli
basi least express us basi drug price know topic convers within
pharma industri constant topic convers potenti evolv go forward realli
say us least -- one point view sorri
give much joy least much inform
pipelin grow high teen year-to-d compar last year ebp segment know
often subject question remain healthi know blockbust year term fund
year-to-d fund track similar also strong year
pipelin late-stag molecul continu expand grow sinc end last year
interestingli oncolog anoth strong quarter across busi
august jess seem like -- think quarter backlog growth rate around would
reason assum next year compani kind top line growth
trend anyth els see backlog would caus number perhap much
lower
think reason expect go forward far futur think current roll-
see -- suspect next -- next year elect cycl uncertainti around
soften believ growth long-term expect
page
confer
take back go elect cycl happen quickli
 decis make trend chang custom
jess geiger medpac hold inc cfo laboratori oper
start see elong fund approach -- fund cycl third quarter
fourth quarter first probabl pay close attent thing --
coupl program take longer get fund work -- thing kept
get longer longer client kept longer fund cycl
kind led earli part saw thing realli elong coupl quarter
time got end thing pick back think program
fund challeng late earli never got fund environ pick back
coupl quarter later head great growth
okay think one ceo quarter ago discuss mayb paus
custom around price concern think come mayb
temporari factor character decision-mak and/or tone busi vi --
vi go washington
mention thing talk client obvious got concern
part whole rational refocus biotech big pharma actual shown
concern polit landscap price
alway prepar worst case scenario tri derisk best
seen impact stay close got larg proport busi work close
leadership team strateg solut natur busi obvious --
take strong concern obvious -- know go shape like certainli
radar big time tri make sure understand effect anyth
need consid today
page
great guess follow commerci side sound like guy feel like delay
whether deploy solut consult revenu declin medic adher
sound like think lot come back alistair point obvious
kind -- big book quarter commerci sens talk
custom behind shortfal anyth broader go thought around delay
push thing around fear drug price environ anyth like
think realli tactic someth kind price play commerci busi
saw quarter
bob discuss custom seem tactic drug price
come much polit environ mean know happen right
daili basi seem anyth kind symptomat underneath seem --
tactic headwind short term think absolut believ short term certainli look level
interest get level rfp get discuss see higher level
term partnership et cetera inclus commerci clinic deliveri well
commerci stand-alon encourag penetr see syneo one
take step back broadli industri anyth point term like
chang fund gener rfp level broadli
elizabeth think fund level -- think biotech fund index -- trend
littl bit think lot custom certainli one dealt year dip
kind market go good lot custom year cash hand
lot buffer think rfp flow normal think seen uplift think get
rfp larger custom see partnership come get kind
longer insight see lift look smid market feel right
rfp flow still pretti strong mean paul thought
page
